EGFR and neoplasm: In fact, the results of our IPA analysis are consistent with these previous studies, which suggest the possibility that Ambrisentan’s inhibitory effects could also involve other tumor-promoting signalling pathways (e.g. EGFR) and transactivation signalling events30–34.